Literature DB >> 26506066

The Natural History of Soft Tissue Hypertrophy, Bony Hypertrophy, and Nodule Formation in Patients With Untreated Head and Neck Capillary Malformations.

Jeong Woo Lee1, Ho Yun Chung, Eric W Cerrati, Teresa M O, Milton Waner.   

Abstract

BACKGROUND: A percentage of patients with capillary malformation (CM) develop soft tissue hypertrophy, bony hypertrophy, and/or nodule formation.
OBJECTIVE: To determine the incidence, age of onset, anatomic distribution of soft tissue/bony hypertrophy, and nodule formation in patients with untreated CM.
METHODS: A retrospective medical records review of head and neck CM patients presenting to a tertiary referral center over a 7-year period (2004-2011) was performed.
RESULTS: Of the 160 patients with CM, 96 demonstrated progression of disease to include either soft tissue/bony hypertrophy or nodule formation. Of these, 87 patients had not received previous treatment and met the inclusion criteria for analysis. On average, soft tissue hypertrophy began at 9 years of age. The V2/maxillary segment was most commonly involved with upper lip hypertrophy being the most prominent. Fourteen percent of the patients also presented with bony hypertrophy, which began at an average age of 15 years. Nodules were present in 38/87 (44%) of patients with an average age of onset of 22 years.
CONCLUSION: This study demonstrates the nature progression of CM and quantifies the clinical characteristics of hypertrophy and nodule formation with untreated head and neck CM. Early and continuous treatment is recommended in hopes of preventing CM progression.

Entities:  

Mesh:

Year:  2015        PMID: 26506066     DOI: 10.1097/DSS.0000000000000525

Source DB:  PubMed          Journal:  Dermatol Surg        ISSN: 1076-0512            Impact factor:   3.398


  7 in total

1.  A New Nonlinear Photothermal Iterative Theory for Port-Wine Stain Detection.

Authors:  Na Cao; Hongtao Liang; Ruoyu Zhang; Yanhua Li; Hui Cao
Journal:  Int J Environ Res Public Health       Date:  2022-05-05       Impact factor: 4.614

2.  Electrosclerotherapy for capillary malformations: study protocol for a randomised within-patient controlled pilot trial.

Authors:  Sophie E R Horbach; Albert Wolkerstorfer; Daniel Martijn de Bruin; Sanne M Jansen; Chantal M A M van der Horst
Journal:  BMJ Open       Date:  2017-11-14       Impact factor: 2.692

3.  Activation of PKCα and PI3K Kinases in Hypertrophic and Nodular Port Wine Stain Lesions.

Authors:  Rong Yin; Lin Gao; Wenbin Tan; Wei Guo; Tao Zhao; Jhon Stuart Nelson; Gang Wang
Journal:  Am J Dermatopathol       Date:  2017-10       Impact factor: 1.533

4.  Clinical outcome measures and scoring systems used in prospective studies of port wine stains: A systematic review.

Authors:  M Ingmar van Raath; Sandeep Chohan; Albert Wolkerstorfer; Chantal M A M van der Horst; Jacqueline Limpens; Xuan Huang; Baoyue Ding; Gert Storm; René R W J van der Hulst; Michal Heger
Journal:  PLoS One       Date:  2020-07-02       Impact factor: 3.240

Review 5.  The Pathogenesis of Port Wine Stain and Sturge Weber Syndrome: Complex Interactions between Genetic Alterations and Aberrant MAPK and PI3K Activation.

Authors:  Vi Nguyen; Marcelo Hochman; Martin C Mihm; J Stuart Nelson; Wenbin Tan
Journal:  Int J Mol Sci       Date:  2019-05-07       Impact factor: 5.923

6.  Individualized Surgical Management of Refractory Port-Wine Stains in the Scalp and Face: A Single-Center Retrospective Study and a Discussion of Surgical Strategies.

Authors:  Qian Wang; Chen Yong; Min Wang; Lei Cui; Si-Ming Yuan
Journal:  Clin Cosmet Investig Dermatol       Date:  2022-08-03

Review 7.  Consensus Statement for the Management and Treatment of Port-Wine Birthmarks in Sturge-Weber Syndrome.

Authors:  Sara Sabeti; Karen L Ball; Craig Burkhart; Lawrence Eichenfield; Esteban Fernandez Faith; Ilona J Frieden; Roy Geronemus; Deepti Gupta; Andrew C Krakowski; Moise L Levy; Denise Metry; J Stuart Nelson; Megha M Tollefson; Kristen M Kelly
Journal:  JAMA Dermatol       Date:  2021-01-01       Impact factor: 10.282

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.